For the quarter ended June 2026, Regeneron (REGN Quick QuoteREGN - Free Report) reported revenue of $4.29 billion, up 16.7% over the same period last year. EPS came in at $14.29, compared to $12.89 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $3.84 billion, representing a surprise of +11.74%. The company delivered an EPS surprise of +42.9%, with the consensus EPS estimate being $10.00.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Eylea (Aflibercept)(EYLEA HD and EYLEA)- US: $1.01 billion compared to the $935.89 million average estimate based on four analysts. The reported number represents a change of -12.1% year over year.
• Revenues- EYLEA HD- United States: $596.3 million compared to the $548.4 million average estimate based on four analysts. The reported number represents a change of +51.7% year over year.
• Revenues- EYLEA- United States: $412.2 million versus $387.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -45.4% change.
• Revenues- Kevzara (sarilumab)- ROW: $62.5 million versus $63.5 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
• Revenues- Collaboration: $2.46 billion compared to the $2.13 billion average estimate based on five analysts. The reported number represents a change of +31.9% year over year.
• Revenues- Other Revenue: $193.3 million versus $232.99 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
• Revenues- Net product sales: $1.64 billion versus the five-analyst average estimate of $1.49 billion. The reported number represents a year-over-year change of +0.7%.
• Revenues- Total Sanofi collaboration revenue: $2.17 billion versus the four-analyst average estimate of $1.76 billion. The reported number represents a year-over-year change of +50.6%.
• Revenues- Total Bayer collaboration revenue: $276 million compared to the $310.83 million average estimate based on four analysts. The reported number represents a change of -33.5% year over year.
• Revenues- Praluent (alirocumab)- Total: $265.6 million versus the three-analyst average estimate of $230.44 million. The reported number represents a year-over-year change of +19.6%.
• Revenues- Libtayo- Total: $489.4 million versus the three-analyst average estimate of $451.13 million. The reported number represents a year-over-year change of +30%.
• Revenues- Kevzara (sarilumab)- Total: $205.9 million versus the three-analyst average estimate of $162.22 million. The reported number represents a year-over-year change of +35.3%.

View all Key Company Metrics for Regeneron here>>>

Shares of Regeneron have returned +11.3% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.